- Filter by
- Categories
- Tags
- Show all
- Article
- Confusion
- Contract
- Copyright
- Corporate
- Domain Names
- Employment
- Expungement
- Expungement
- Grey Marketing
- Industrial Designs
- Licensing
- Obviousness
- Opposition
- Passing Off
- Patent
- Patent Infringement
- Patent Strategy
- PM(NOC)
- Procedure
- Prosecution
- recognition
- Services
- Summary
- Trade Secrets
- Trade-mark
- Use
- Validity
- 35 US Code §101
- 3D printing
- Abandonment
- abstract theorems
- Accounting of Profits
- acquired distinctiveness
- actions
- actual notice
- agreement
- Alice/Mayo Test
- Ambiguity
- Amendments
- annual maintenance fee
- Anticipation
- Appeal
- application
- application fee
- arbitrary
- arbitration
- Assignment
- Australia
- Bad Faith
- Bargain Theory
- Bill C-31
- Bill C-43
- Bill C-8
- Bill C-86
- Biologics
- biosimilar
- Biotech Patents
- Blockchain
- border measures
- Brand
- broadcasting
- budget
- burden of proof
- business
- CAFC
- Canada
- Canada Gazette
- Cannabis Law
- causal link
- cdrp
- CEEO
- Certificate of Supplementary Protection
- champerty
- Chemical Patent
- chemistry
- ciba
- CIPO
- CIPO errors
- CIRA
- Claim Construction
- Class Actions
- clerical error
- college of agents
- combination drugs
- commissioner
- Common General Knowledge
- Complete Code
- confidential
- Confidential Information
- confidentiality
- confidentiality order
- Conflict of Interest
- Confusion
- Constitution
- constitutionality
- consumer goods
- contract
- contributory infringement
- Copyright
- Copyright Infringement
- copyright test
- corrections
- Costs
- counterfeit
- COVID-19
- CSP
- cybersecurity
- Damages
- Data
- Data Protection
- deadline
- deadlines
- defamation
- defences
- delay to market entry
- delayed market entry
- descriptive
- Design Patents
- deviation
- digital infringement
- disclosure
- distinctiveness
- Diversity
- division of powers
- divisionals
- DNA Patents
- domain names
- dominant feature
- Dosage Range
- Double Patenting
- doubtful cases
- due care
- E-Commerce
- Early dismissal
- economics
- Employment
- errors
- essentiality of elements
- Ethics
- Europe
- Events
- Evidence
- examination quality
- examination statistics
- Examiner
- expert
- expert blinding
- expert evidence
- Experts
- expiry
- Expungement
- extraterritoriality
- Fair Use
- federal circuit
- Federal Court
- Federal Court of Appeal
- fees
- file wrapper
- Filing
- filing date
- filing fee
- financial services
- foreign issue estoppel
- forum selection
- fraud
- Free World Trust
- frivolous
- funding
- future infringement
- generics
- geographical indications
- Good Faith
- goods
- Government
- grace period
- grey marketing
- Hague
- hearsay
- hearsay evidence
- Honest Contractual Performance
- ICSID
- Illegality
- Improver
- Indefiniteness
- Inducement
- Industrial Designs
- inherent distinctiveness
- injunction
- Injunctions
- Innovation
- insufficiency
- insufficient disclosure
- Intellectual Property
- intent
- Inter Partes Review
- interlocutory injunction
- Internet
- intra vires
- invalidated
- invalidation
- inventor removal
- inventorship
- IP Lawyer
- ip regime
- IP Strategy
- IPIC
- IPO
- ISP
- IT patent
- ITC
- Jurisdiction
- Late fee
- Legal Retainer
- legal test
- legislative reform
- Licensing
- life science
- limitation periods
- Litigation
- litigation evidence
- litigation funding agreement
- madrid
- maintenance
- materiality
- method
- Methods of Medical Treatment
- misleading
- motion
- Motion to dismiss
- Motion to strike
- NAFTA
- national phase entry
- new act
- new evidence
- no chance of success
- Non-Infringing Alternative
- notice of allegation
- notice to rectify
- Novelty
- obivous error
- Obviousness
- Office
- official mark
- official marks
- on-sale
- on-sale bar
- Online
- ontario
- opposition
- Overbreadth
- ownership
- Ownership & Inventorship
- Passing Off
- patent abandonment
- Patent Act
- patent agent
- Patent Agents
- patent appeal board
- Patent Application
- Patent Drafting
- Patent Infringement
- Patent Litigation
- Patent Office
- patent office errors
- patent owner
- patent ownership
- patent practicioner
- patent prosecution
- patent requirement
- Patent Rules
- Patent Strategy
- patent term adjustment
- Patent Textbook
- Patent Trial and Appeal Board
- Patent Trolls
- patentability
- Patentable Subject Matter
- Patents
- PCT
- Pharmaceutical Patent
- Pharmaceutical Pricing
- PLT
- PM(NOC)
- PM(NOC) Damages
- PMPRB
- POSITA
- price regulation
- pride
- prior art
- prior use
- priority
- priority claim
- priority claims
- priority date
- Privilege
- procedure
- Product Specificity
- prohibited marks
- Promise Doctrine
- proprietor
- Prosecution
- Prosecution History
- protective order
- prothonotaries
- Provisional Patent
- public sale
- Public Servant
- Punitive Damages
- Recognition
- Records
- registration
- reinstatement
- Remedies
- representation
- request for correction
- requisition
- responding
- review
- risk
- Royalties
- s. 27
- s. 45
- s. 53
- sale
- Scheduling
- SCOTUS
- second person
- Secondary Infringement
- secondary meaning
- secret sale
- section 28
- Section 45
- section 50
- Section 52
- section 56
- section 7
- security
- selection patents
- Services
- settlement
- Site-Blocking Orders
- skilled person
- software
- Software Copyright
- Software Patent
- software patents
- Sound Prediction
- specification
- sponsorship
- SRED
- Standard of Review
- Standard-Essential Patents
- standing
- standing to appeal
- Start-up
- Startups
- statute of monopolies
- stay
- Strategy
- Sufficiency
- Summary Judgment
- summary trial
- superior court
- Supreme Court of Canada
- surname
- Technology
- Telecommunications
- time frame
- TPP
- Trade Secrets
- Trade-Mark
- Trademark
- Trademark Infringement
- Trademark Opposition
- Trademark Trial and Appeal Board
- Trademarks Act
- treaty
- UK
- united kingdom
- United States
- Use
- useful article
- USMCA
- USPTO
- Utility
- Validity
- Variant
- Varying records
- Velocity
- vexatious
- who's who legal
- Written Description
April 3, 2019
April 3, 2019
Hikma Pharmaceuticals v. Vanda Pharmaceuticals, SCOTUS Docket No. 18-817 - The beginning of the end for method of treatment patents?
February 5, 2015
February 5, 2015
AbbVie Biotechnology Ltd v Canada (Attorney General), 2014 FC 1251 - The core of the Commissioner’s argument was that Janssen Inc v Mylan Pharmaceuticals ULC, 2010 FC 1123, broadened the prohibition against patents on methods of medical treatment to include generally claims which restrict the “how and when” a physician could administer a particular drug. The Court found that the Commissioner had misread Janssen.
December 23, 2013
December 23, 2013
Re. Application 2,365,923 CD 1343 Background The Application is for a patent for the use of a drug to treat patients suffering from a rare genetic […]
October 29, 2013
October 29, 2013
Bayer Inc. v Cobalt Pharmaceuticals Company [2013 FC 1061] Background This proceeding is an application under the NOC regulations by Bayer seeking a prohibition order to […]
June 13, 2013
June 13, 2013
Effective June 10, 2013 PN2013-04 This Practice Notice builds upon the guidance in section 17.02.03 (Medical and surgical methods) of MOPOP and in PN 2013-02 (Examination […]